News
Vantia Therapeutics announces £4 million fund raising
6 July 2011
Vantia Therapeutics raises £4 million to fund clinical development of lead compounds.
Vantia appoints new CEO
9 June 2010
Vantia Therapeutics announces that it has appointed Andrew Crockett to the position of Chief Executive Officer.
Business Development
Vantia Therapeutics' strategy is to develop its proprietary drug candidates through Phase II clinical testing and commercialise through partnerships.
For more information on the product opportunities in development, please contact:
-
Andy Crockett (CEO) or Robert Tansley (Director of Business Development)
Tel: +44 23 8076 3400
E-mail: bus.dev@vantia.com
